EXCLUSIVE: Pfizer plans to move fast on rare disease pacts

Pfizer went public with its new rare disease unit earlier this week, but one of its top execs has been working away for the past few months setting up a division that is preparing to team up with a range of biotechs on new therapeutics. "This morning at 7 a.m. I was at breakfast, talking to a company," Jose Carlos Gutierrez-Ramos, Pfizer's Cambridge-based senior vice president for biotherapeutics research and development, tells FierceBiotech. "We are actively talking to people and have been for...